Human herpesvirus-6 DNA in the saliva of paediatric oncology patients and controls

✍ Scribed by Dr. E. G. H. Lyall; H. A. Cubie

• Publisher: John Wiley and Sons
• Year: 1995
• Tongue: English
• Weight: 602 KB
• Volume: 47
• Category: Article
• ISSN: 0146-6615
• DOI: 10.1002/jmv.1890470405

✦ Synopsis

Abstract

Children with malignancy are immunosup‐pressed and susceptible to serious infections with herpesviruses. The majority of children on chemotherapy for malignancy are seropositive for human herpesvirus‐6 (HHV‐6), and although HHV‐6 has been demonstrated to be a pathogen in severely immunocompromised patients, whether this is the case for paediatric oncology patients is unknown.

HHV‐6 is secreted in saliva and in this study samples were examined prospectively for HHV‐6 DNA in healthy children and those with malignancy. In a nested polymerase chain reaction (PCR), a 287 bp outer fragment and 163 inner fragment of HHV‐6 DNA were amplified. The resulting amplimer contained a Hind III restriction site present only in “B” type HHV‐6 and this was used to identify the type of HHV‐6 amplified. In saliva from healthy control children, 74% (28/38) of samples were HHV‐6 DNA‐positive in either the supernate, pellet or both. In the patients, 58% (45/77) of all samples were HHV‐6 DNA‐positive. When sequential samples from twelve patients were examined the children appeared to fall into two groups: those who were frequently HHV‐6 DNA‐positive (60% of samples or more) and those who were rarely HHV‐6 DNA‐positive (33% of samples or less) (P < 0.0001). The only apparent difference between these two groups was that the less frequently HHV‐6‐positive group was more often febrile and unwell with neutro‐paenia. Hind III digestion demonstrated all the positive samples to be “6” type HHV‐6. Possible explanations for this difference in HHV‐6 secretion between the patient groups are discussed. © Wiley‐Liss, Inc.